TGR-1202 + oxaliplatin + folinic acid + fluorouracil + bevacizumab

This is a multi-drug **combination regimen** comprising TGR-1202 (umbralisib, a PI3K delta inhibitor), oxaliplatin (a platinum-based chemotherapy), folinic acid (leucovorin, a form of reduced folic acid used to enhance fluorouracil potency), fluorouracil (a pyrimidine analog antimetabolite), and bevacizumab (a monoclonal antibody targeting VEGF). **TGR-1202** inhibits the PI3K delta pathway, modulating B-cell signaling and tumor growth[4]. **Oxaliplatin** causes DNA crosslinking, inhibiting DNA replication. **Folinic acid** enhances the cytotoxicity of fluorouracil by stabilizing the FdUMP-thymidylate synthase complex. **Fluorouracil** interferes with DNA and RNA synthesis. **Bevacizumab** binds to and neutralizes VEGF-A, inhibiting tumor angiogenesis. This combination may be explored in resistant/refractory hematologic malignancies or solid tumors but is not a standard named regimen; each component is FDA approved for various cancers, and some are established in combination (e.g., FOLFOX + bevacizumab in colorectal cancer), but the addition of TGR-1202 is investigational.

Brand names

umbralisib

Other names

oxaliplatinfolinic acidleucovorinfluorouracil5-fluorouracil5-FU